Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches
K Mitusova, OO Peltek, TE Karpov… - Journal of …, 2022 - Springer
Besides the broad development of nanotechnological approaches for cancer diagnosis and
therapy, currently, there is no significant progress in the treatment of different types of brain …
therapy, currently, there is no significant progress in the treatment of different types of brain …
Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer
PR Kennedy, M Felices, JS Miller - Stem Cell Research & Therapy, 2022 - Springer
Natural killer (NK) cells are innate immune cells that recognize malignant cells through a
wide array of germline-encoded receptors. Triggering of activating receptors results in …
wide array of germline-encoded receptors. Triggering of activating receptors results in …
Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Background With the increasing use of immune checkpoint inhibitors (ICIs) for tumour
immunotherapy, the immune-related adverse events (irAEs) caused by their collateral effect …
immunotherapy, the immune-related adverse events (irAEs) caused by their collateral effect …
Identification of neural progenitor cell-associated chemoradiotherapy resistance gene set (ARL4C, MSN, TNFAIP6) for prognosis of glioma
Y Yang, X Xu, Y Xie, Y Liu, C Ning, Y Ai… - Current …, 2022 - ingentaconnect.com
Background: Glioma is the most common malignant intracranial tumor with high lethality.
Despite surgery combined with chemoradiotherapy, the prognosis for patients with glioma …
Despite surgery combined with chemoradiotherapy, the prognosis for patients with glioma …
Exploring Brain-Derived Progenitor Cells as a therapeutic delivery system to Glioblastoma
AT Olin - 2023 - search.proquest.com
Glioblastoma (GBM) is a devastating incurable malignant brain cancer in need of new
treatments. We have begun to investigate the feasibility of a primary adult cell type …
treatments. We have begun to investigate the feasibility of a primary adult cell type …
Delivery strategies for immune checkpoint blockade
R Zhu, T Lang, Q Yin, Y Li - Systemic Drug Delivery Strategies, 2022 - Elsevier
Immune checkpoint blockade (ICB) with immune checkpoint inhibitors (ICIs) which includes
monoclonal antibodies, peptides, nucleotides, and small molecules has become one of the …
monoclonal antibodies, peptides, nucleotides, and small molecules has become one of the …